| Disease Condition |
Therapeutic outcome achieved |
| Sickle cell disease |
Improvement of hematopoiesis at functional and physiological levels |
| Hemophilia A |
- Survival benefit obtained
- Decreased clotting time achieved |
| Parkinson's disease |
Dopamine production enhanced, leading to symptomatic improvement |
| Ischemic heart disease |
In situ tissue repair leading to improved cardiac performance |
